COMPANY DECK
PLATFORM
Aging: The elephant in the room
The key challenge in age-related therapeutics is separating the irreversible background of aging from the reversible disease mechanisms
Current technologies struggle to
Why is aging of long-living species practically irreversible?
To drive the multifold increase in clinical trial success against age-related diseases, we are dedicated to delivering therapeutics which will potentially cure age-related diseases.
Why did entropic aging used to be overlooked?
The research is typically conducted with short-time scale experiments on short-lived cell and animal models, focusing on microscopic-scale mechanisms. The effects of entropic aging are too rare, small and random, to be identified this way.
But why do all humans tend to have the same age-related diseases?
When the pressure of entropic aging becomes significant we can observe the organism’s response to it (sterile inflammation/senescence) resulting in overall frailty. This is why all hallmarks of aging are correlated late in life and are potentially reversible.
Gero aims to overcome the challenges of drug discovery for age-related diseases by inverting the starting point of drug discovery from the microscopic, short-time scale to the macroscopic, long-time scale.
OUR SOLUTION
Separating the effects of aging from the mechanisms of diseases in real-world data for in-human target identification
We have leveraged our background in the physics of complex systems to train a very Large generative Model of human Health (LHM) on a dataset of tens of millions longitudinal, real-world medical histories. The model is unsupervised and can predict future health outcomes similarly to how Large Language Models (LLM) anticipate the next word in a sentence. However, unlike LLMs, our models are physics-based and fully interpretable. It allows us to build clinically relevant disease progression models (phenotypes) in real-world human data and only then look for genetic and molecular factors that control them over long periods of time.
Aging
The main driver behind chronic diseases
In-human
target & drug discovery
By integrating LHM with rich molecular data (such as whole-exome sequencing), we unveil novel treatments for chronic age-related diseases both in-house and in collaborations with pharmaceutical companies.
